By Robert Preidt HealthDay reporter
Monday, May 16, 2022 (HealthDay News) – As the United States mourns one million deaths from COVID-19, a new study suggests the gloomy figure could have been worse. Use of Pfizer-BioNTech COVID-19 vaccine In 2021, more than 110,000 deaths were prevented in the United States և 690,000 hospitalizations, researchers report.
The vaccine also prevented 8.7 million symptomatic cases of the infection, saved more than $ 30 billion in health care costs, and lost more than $ 40 billion in productivity, the study authors said.
“Analyzes show that the Pfizer-BioNTech COVID-19 vaccine has had a significant impact on public health in the United States in 2021, with a profound impact on the course of the disease. pandemicSaid Manuela Di Fusco of Pfizer’s Health Economics և Results Research Team.
The Pfizer vaccine was the first COVID-19 vaccine available in the United States. According to the US Centers for Disease Control and Prevention, it was given to 10 to 6 people across the country who were fully vaccinated in 2021.
The research was published online on May 15 Journal of Medical Economics. All authors of the study received funding from Pfizer, either as employees, consultants, or employees of companies paid by Pfizer.
Despite the use of COVID-19 vaccines, the death toll from the epidemic in the United States reached one million last week.
President Joe Biden ordered the US flags to be flown on Thursday.
“We have to be vigilant against this epidemic and do everything we can to save as many lives as possible,” Biden said.
In this study, researchers evaluated the effectiveness of the Pfizer vaccine using model, real-world data, and clinical trial data.
The model used data on the number of people vaccinated, the effectiveness of the vaccine in different age groups, the chances of infection, the development of symptoms, and the chances of hospitalization.
It also included the consequences long COVIDThe number of working days lost due to a short illness; the economic impact of premature deaths from the disease.
The model does not include the effect of more transferability Omicron version: which became the predominant coronavirus strain at the end of the study period.
“The vaccine was estimated to prevent millions of COVID-19 symptoms, thousands of hospitalizations, deaths, and generated billions of socio-economic value in the United States in 2021,” Di Fusco said in a news release.
The findings “highlight the potential for continued vaccination to prevent COVID-19-associated disease and generate public benefits,” he added.
According to Di Fusco և’s colleagues, a number of restrictions could lead to an underestimation of the survey figures. These include not recognizing the potential of the vaccine to reduce coronavirus transmission, the severity of cases, and the “long-term” overall effect of COVID.
The researchers also said that their findings could not be applied to other COVID-19 vaccines or groups of people that were not specifically analyzed in the study.
Find out more about COVID-19 vaccines at US Centers for Disease Control and Prevention.
SOURCE: Journal of Medical Economics, news release, May 16, 2022